Читать книгу Transporters and Drug-Metabolizing Enzymes in Drug Toxicity - Albert P. Li - Страница 66

Nefazodone is a phenylpiperazine antidepressant which received approval from the Food and Drug Administration for treatment of major depressive disorder in 1994. Nefazodone enhances serotonin (5‐hydroxytryptamine [5‐HT]) synaptic transmission by acting as a potent antagonist of 5‐HT2 receptors and as a 5‐HT uptake inhibitor (SARI) as well as a weak serotonin‐norepinephrine‐dopamine uptake inhibitor (SNDRI) [105–109]. Nefazodone is efficacious toward the treatment of depression with depression‐related anxiety symptoms [106]. Nefazodone administration has been found to be associated with the occurrence of idiosyncratic liver failure resulting in deaths and a need for liver transplantation [110–115]. Nefazodone was withdrawn from the US market in 2004 [116, 117]. A survey of Canadian patients shows that a majority of the patients with nefazodone‐induced liver injuries occurred within eight months of administration [118].